The Typical Case Resport And Literature Analysis Of Chimeric Antigen Receptor T-cell Immunotherapy In B-cell Lymphoma

Tumor immunotherapy is to stimulate or mobilize the body’s immune system,restore and enhance the patient’s own immune monitoring and tumor killing function.It has the advantages of strong specificity,small side effects,good safety,etc,and can effectively kill the tumor cells remaining in the body after surgery and chemoradiotherapy,which is one of the important means to prevent and treat postoperative recurrence and advanced tumor in tumor patients.Chimeric antigen receptor T cell(CAR-T)therapy is a rapidly developed adoptive cell therapy in recent years,and has achieved remarkable results in the treatment of hematologic malignancies.There have been approved by the us FDA for the treatment of hematologic tumors of CAR T cell products targeting CD19.The key to tumor cell immunotherapy is to select the ideal tumor antigens as target,which were specific expressed in cancer cells,but not in any normal adult tissue cells.So that the immune cells can kill tumor cells at the same time,avoid serious toxic side effects or autoimmune diseases caused by the attack of normal tissues or important organs.Studies have shown that CD19 molecules are often expressed stably on the surface of tumor cells of B-cell lymphoma,which provides an ideal tumor antigen target for immune cell therapy.Malignant lymphoma is a malignant tumor originating from lymph nodes and/or outside lymph nodes.Although some targeted drugs on the market have greatly improved the prognosis of patients,there are still 20-30% of patients with refractory recurrence who develop drug resistance to recurrence and have a low rate of complete remission.Studies have shown that the overall remission rate for recurrent non-hodgkin’s tumors is less than 20%.Therefore,it is necessary to search for new therapies for recurrent refractory diffuse large B-cell lymphoma.The typical cases were reported of CAR-T treatment for gastric lymphoma,and current clinical studies on CAR-T cell therapy for B-cell lymphoma were reviewed and Shared.The patient has diffuse large b-cell lymphoma and received cell transfusion,Long-term follow-up showed that the patient’s CR was up to 25.8 months.The most common adverse events were fever,mild and cold chills,headache and low globulin hematic disease,et al.At present,domestic and foreign clinical studies on b-cell lymphoma have shown that car-t cells have good safety and tolerance in the treatment of b-cell lymphoma.